The # 1 biomarker for Alzheimer’s is amyloid plaques in the brain. Research has found that retinal amyloid plaques directly correlate to the plaques in the brain, and they present far, far earlier than dementia symptoms. Studying retinal changes signals early AD detection and early therapies. Click here to learn more.
Recent Posts
Archive
- January 2019 (2)
- December 2018 (5)
- November 2018 (6)
- October 2018 (4)
- September 2018 (4)
- August 2018 (4)
- July 2018 (5)
- June 2018 (5)
- May 2018 (3)
- April 2018 (8)
- March 2018 (6)
- February 2018 (4)
- January 2018 (5)
- December 2017 (5)
- November 2017 (2)
- October 2017 (2)
- September 2017 (4)
- August 2017 (5)
- June 2017 (3)
- May 2017 (3)
- April 2017 (7)
- March 2017 (10)
- February 2017 (4)
- January 2017 (6)
- December 2016 (6)
- November 2016 (8)
- October 2016 (9)
- September 2016 (8)
- August 2016 (4)
- July 2016 (7)
- June 2016 (8)
- May 2016 (12)
- April 2016 (14)
- March 2016 (10)
- February 2016 (11)
- January 2016 (1)
- June 2015 (1)
August 2017
.jpg)
At long last, Sickle Cell Disease has a new treatment. It has proven to reduce the debilitating effects of the disorder and to decrease the need for hospitalizations. Click here to learn more.
By combining 2 chemotherapy drugs into 1 treatment improves results for high-risk AML patients. The effects are synergistic. The partnership has shown significantly improved results than either drug working alone. Click here to learn more.
The newly developed MRI device allows fragile neonates to remain in the NICU for head imaging. Urgent access to the infant is maintained at all times. Because the unit is full enclosed, the safety of others in the environment is ensured. Click here to learn more.
.jpg)
Recent research suggests that thrombocytosis could be an early sign of cancer and relevant to primary care as a red flag for further investigation. With no other cancer symptoms, thrombocytosis can prompt early diagnosis and could be the key to survival and better recovery. Click here to learn more.